Home > Insider Trading > Filing (0001415889-23-016423)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1159036	Halozyme Therapeutics Inc.	HALO	Biological Products, (No Disgnostic Substances) (2836)	880488686

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1507174	J. Michael Labarre	C/O Halozyme Therapeutics, Inc. 12390 El Camino Real San Diego CA 92130	Svp, Chief Technical Officer	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2023-12-12	8,533	$13.81	160,444	No	4	M	Direct
Common Stock	Acquisiton	2023-12-12	1,467	$12.07	161,911	No	4	M	Direct
Common Stock	Disposition	2023-12-12	9,357	$39.58	152,554	No	4	S	Direct
Common Stock	Disposition	2023-12-12	643	$40.47	151,911	No	4	S	Direct
Common Stock	Acquisiton	2023-12-13	10,000	$12.07	161,911	No	4	M	Direct
Common Stock	Disposition	2023-12-13	10,000	$40.39	151,911	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Option to Purchase Common Stock	Disposition	2023-12-12	8,533	$0.00	8,533	$13.81
Common Stock	Option to Purchase Common Stock	Disposition	2023-12-12	1,467	$0.00	1,467	$12.07
Common Stock	Option to Purchase Common Stock	Disposition	2023-12-13	10,000	$0.00	10,000	$12.07

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2025-02-04	No	4	M	Direct
54,885	2027-02-22	No	4	M	Direct
44,885	2027-02-22	No	4	M	Direct

Footnotes

The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.
Represents a weighted average sales price per share. These shares were sold at prices ranging from $39.25 to $40.19. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Represents a weighted average sales price per share. These shares were sold at prices ranging from $40.315 to $40.50. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Represents a weighted average sales price per share. These shares were sold at prices ranging from $40.20 to $40.72. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
This option was granted on February 4, 2015 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.
This option was granted on February 22, 2017 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.